https://genomethods.org/signal/vanderbilt-team-unlocks-molecular-secrets-in-decades-old-human-tissue-96910/GenoMethods.orgen2026-09-22T15:39:00-07:00Vanderbilt team unlocks molecular secrets in decades-old human tissuehttps://genomethods.org/signal/single-crispr-infusion-cuts-stubborn-ldl-cholesterol-for-a-year-96909/GenoMethods.orgen2026-09-22T13:42:00-07:00Single CRISPR infusion cuts stubborn LDL cholesterol for a yearhttps://genomethods.org/signal/precure-llc-and-helix-launch-million-sample-multiomics-push-at-mayo-clinic-96908/GenoMethods.orgen2026-09-22T11:46:00-07:00Precure LLC and Helix launch million-sample multiomics push at Mayo Clinichttps://genomethods.org/signal/regulatory-hurdles-put-city-of-hope-s-panxeon-pancreatic-cancer-test-to-the-test-96868/GenoMethods.orgen2026-09-22T10:59:00-07:00Regulatory hurdles put City of Hope's PANXEON pancreatic cancer test to the testhttps://genomethods.org/signal/genomic-mapping-unlocks-new-insights-into-threatened-asian-hornbills-96824/GenoMethods.orgen2026-09-22T09:34:00-07:00Genomic mapping unlocks new insights into threatened Asian hornbillshttps://genomethods.org/signal/phase-iii-trial-data-volumes-double-every-seven-years-as-complexity-becomes-the-new-normal-96752/GenoMethods.orgen2026-09-22T08:22:00-07:00Phase III trial data volumes double every seven years as complexity becomes the new normalhttps://genomethods.org/signal/australian-government-funds-international-car-t-clinical-trials-for-children-96753/GenoMethods.orgen2026-09-22T06:45:00-07:00Australian government funds international CAR-T clinical trials for childrenhttps://genomethods.org/signal/uzbekistan-plans-biome-center-for-cell-technologies-and-genomics-96737/GenoMethods.orgen2026-09-21T23:37:00-07:00Uzbekistan plans Biome center for cell technologies and genomicshttps://genomethods.org/signal/sidra-medicine-develops-genomic-tool-to-predict-risk-of-cognitive-decline-96738/GenoMethods.orgen2026-09-21T22:32:00-07:00Sidra Medicine develops genomic tool to predict risk of cognitive declinehttps://genomethods.org/signal/gene-editing-strategies-take-center-stage-in-malaria-research-at-mdu-96739/GenoMethods.orgen2026-09-21T20:25:00-07:00Gene editing strategies take center stage in malaria research at MDUhttps://genomethods.org/signal/ai-designed-genome-editors-offer-new-options-for-rice-gene-editing-96740/GenoMethods.orgen2026-09-21T19:22:00-07:00AI-designed genome editors offer new options for rice gene editinghttps://genomethods.org/signal/briacell-therapeutics-advances-off-the-shelf-cancer-immunotherapy-into-late-stage-clinical-trials-96754/GenoMethods.orgen2026-09-21T18:26:00-07:00BriaCell Therapeutics advances off-the-shelf cancer immunotherapy into late-stage clinical trialshttps://genomethods.org/signal/cardinal-health-targets-double-digit-earnings-growth-as-specialty-business-expands-96771/GenoMethods.orgen2026-09-21T16:01:00-07:00Cardinal Health targets double-digit earnings growth as specialty business expandshttps://genomethods.org/signal/ai-patient-profiling-challenges-the-meaning-of-failed-clinical-trials-96756/GenoMethods.orgen2026-09-21T14:20:00-07:00AI patient profiling challenges the meaning of failed clinical trialshttps://genomethods.org/signal/abbvie-pursues-dual-antibody-strategy-to-reshape-lung-cancer-treatment-96757/GenoMethods.orgen2026-09-21T13:16:00-07:00AbbVie pursues dual antibody strategy to reshape lung cancer treatmenthttps://genomethods.org/signal/ireland-s-cell-therapy-sector-depends-on-imports-as-demand-for-activation-beads-rises-96758/GenoMethods.orgen2026-09-21T12:11:00-07:00Ireland’s cell therapy sector depends on imports as demand for activation beads riseshttps://genomethods.org/signal/uk-and-israel-pursue-new-science-and-tech-partnerships-despite-political-tensions-96741/GenoMethods.orgen2026-09-21T09:23:00-07:00UK and Israel pursue new science and tech partnerships despite political tensionshttps://genomethods.org/signal/car-t-therapy-transforms-relapsed-lymphoma-into-a-race-for-treatment-access-96760/GenoMethods.orgen2026-09-21T07:52:00-07:00CAR-T therapy transforms relapsed lymphoma into a race for treatment accesshttps://genomethods.org/signal/gujarat-themis-biosyn-completes-rs-1-200-crore-acquisition-of-microbiopharm-japan-96772/GenoMethods.orgen2026-09-21T05:41:00-07:00Gujarat Themis Biosyn completes Rs 1,200 crore acquisition of MicroBiopharm Japanhttps://genomethods.org/signal/latus-bio-brings-on-new-board-leaders-as-gene-therapy-trials-approach-96773/GenoMethods.orgen2026-09-20T22:36:00-07:00Latus Bio brings on new board leaders as gene therapy trials approachhttps://genomethods.org/signal/lokahi-therapeutics-extends-partnership-with-university-of-alabama-for-hands-on-biotech-asset-scouting-96774/GenoMethods.orgen2026-09-20T20:33:00-07:00Lōkahi Therapeutics extends partnership with University of Alabama for hands-on biotech asset scoutinghttps://genomethods.org/signal/ai-designs-new-viruses-to-fight-bacteria-and-rewrites-the-rules-of-biotechnology-96743/GenoMethods.orgen2026-09-20T19:38:00-07:00AI designs new viruses to fight bacteria and rewrites the rules of biotechnologyhttps://genomethods.org/signal/bristol-myers-squibb-s-arlo-cel-meets-phase-ii-goal-in-relapsed-multiple-myeloma-96761/GenoMethods.orgen2026-09-20T17:30:00-07:00Bristol Myers Squibb's arlo-cel meets phase II goal in relapsed multiple myelomahttps://genomethods.org/signal/gene-edited-rice-faces-backlash-as-coalition-demands-urgent-policy-reversal-in-india-96745/GenoMethods.orgen2026-09-20T16:30:00-07:00Gene edited rice faces backlash as coalition demands urgent policy reversal in India